Vestibular Suppressants for Benign Paroxysmal Positional Vertigo: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Sameer Sharif,Danya Khoujah,Alisha Greer,James G. Naples,Suneel Upadhye,Jonathan A. Edlow
DOI: https://doi.org/10.1111/acem.14608
2022-10-23
Academic Emergency Medicine
Abstract:Background Benign paroxysmal positional vertigo (BPPV) is a common cause of acute dizziness. Medication use for its treatment remains common despite guideline recommendations against their use. Objectives To evaluate the efficacy and safety of vestibular suppressants in patients with BPPV as compared to placebo, no treatment, or canalith repositioning maneuvers (CRM). Methods We searched MEDLINE, Cochrane, EMBASE, and ClinicalTrials.gov from inception until March 25th, 2022 for randomized controlled trials (RCTs) comparing anti‐histamines, phenothiazines, anticholinergics, and/or benzodiazepines to placebo, no treatment, or a CRM. Results Five RCTs, enrolling 296 patients, were included in the quantitative analysis. We found that vestibular suppressants may have no effect on symptom resolution at the point of longest follow‐up (14‐31 days in four studies) when evaluated as a continuous outcome (Standardized Mean Difference ‐0.03 points; 95% CI ‐0.53 to 0.47). Conversely, CRMs may improve symptom resolution at the point of longest follow‐up as a dichotomous outcome when compared to vestibular suppressants (Relative Risk [RR] 0.63; 95% CI, 0.52 to 0.78). Vestibular suppressants had an uncertain effect on symptom resolution within 24 hours (Mean Difference [MD] 5 points; 95% CI ‐16.92 to 26.94), repeat Emergency Department (ED)/clinic visits (RR 0.37; 95% CI 0.12 to 1.15), patient satisfaction (MD 0 points; 95% CI ‐1.02 to 1.02), and quality of life (MD ‐1.2 points; 95% CI ‐2.96 to 0.56). Vestibular suppressants had an uncertain effect on adverse events. Conclusions In patients with BPPV, vestibular suppressants may have no effect on symptom resolution at the point of longest follow‐up; however, there is evidence towards the superiority of CRM over these medications. Vestibular suppressants have an uncertain effect on symptom resolution within 24 hours, repeat ED/clinic visits, patient satisfaction, quality of life, and adverse events. This data suggests that a CRM, and not vestibular suppressants, should be the primary treatment for BPPV.
emergency medicine